[Costs of chronic dialysis in a public hospital: myths and realities].
In this study regular dialysis treatment costs during 1998 and 1999 in a public hospital, which is responsible for a population of 178,000, has been analysed. Hemodialysis (HD) and peritoneal dialysis (PD) costs have been differentiated and compared with those of external providers. The best technical and productive efficiency of both treatments have been estimated by analyzing the "treatment cost/human resources of the community utilized" relationship. The HD treatment costs per patient per year were 20,343 and 18,871 euros in 1988 and 1,999, respectively, lower than the costs reported in other studies. In 1999 these costs were similar to those of external providers and lower than the PD treatment costs (23,295 euros). HD retains its advantage even after costs of erythropoietin, hospital admissions and transport are included. In the hospital studied, the best technical efficiency in HD would be reached with 64 patients on treatment (17,851 euros per patient per year) and in PD with 48 patients (21,167 euros per patient per year). If we take into account our population characteristics and consider a patient distribution of 70% on HD and 30% on PD, the best productive efficiency would be reached with 56 patients on HD (17,916 euros per patient per year) and 24 patients on PD (21,813 euros per patient per year). HD confers the greatest economic and social benefits on the population supplied by the hospital since it provides the community with more jobs than PD in relation to treatment costs while the two yield the same clinical results. In conclusion, HD in a public hospital, at least in our environment, may be efficient and competitive with HD from external providers and it may be more efficient and provide a bigger economic and social profit for the population serviced by the hospital than PD, at least while the current supply systems for this treatment in our country are maintained.
Lamas
J
J
Unidad de Nefrología, Hospital Meixoeiro, 36200 Vigo.
Alonso
M
M
Saavedra
J
J
García-Trío
G
G
Rionda
M
M
Ameijeiras
M
M
D000328:Adult; D000368:Aged; D000740:Anemia / Q000188:drug therapy / Q000191:economics; D003362:Cost-Benefit Analysis; D003955:Diagnostic Tests, Routine / Q000191:economics; D016527:Drug Costs / Q000706:statistics & numerical data; D004865:Equipment and Supplies, Hospital / Q000191:economics; D004921:Erythropoietin / Q000191:economics / Q000627:therapeutic use; D005260:Female; D017048:Health Care Costs / Q000706:statistics & numerical data; D017721:Hospital Costs / Q000706:statistics & numerical data; D006757:Hospital Units / Q000191:economics; D006779:Hospitals, Public / Q000191:economics*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000191:economics / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis / Q000191:economics*; D010564:Personnel, Hospital / Q000191:economics; D006435:Renal Dialysis / Q000191:economics*; D012456:Salaries and Fringe Benefits / Q000191:economics; D013030:Spain; D014187:Transportation of Patients / Q000191:economics
D004921:Erythropoietin